2024
Validation of Metallothionein Immunohistochemistry as a Highly Sensitive Screening Test for Wilson Disease
Stokes N, Patil A, Adeyi O, Bhalla A, Brown I, Byrnes K, Calderaro J, Chen D, Chen W, Cooper C, Dhall D, Frankel W, Gooch G, Gonzalez R, Hammer S, Hale G, Lagana S, McKenzie C, Allende D, Moreira R, Nakhleh R, Nalbantoglu I, Pai R, Salomao M, Schaeffer D, Shih A, Shin J, Simoes C, Vij M, Rela M, Xue Y, Yantiss R, Sabatto B, Graham R. Validation of Metallothionein Immunohistochemistry as a Highly Sensitive Screening Test for Wilson Disease. Modern Pathology 2024, 38: 100628. PMID: 39384020, DOI: 10.1016/j.modpat.2024.100628.Peer-Reviewed Original ResearchWilson's diseaseHistological featuresRare autosomal recessive conditionChronic cholestatic diseaseProtean clinical manifestationsEvaluation of patientsAutosomal recessive conditionSensitive screening testCase of WDCost-effective screening toolRoutine histologic sectionsMedian ageNeedle biopsyCholestatic diseasesWD patientsFibrosis stageClinical manifestationsHistopathological patternsATP7B mutationsHistological patternWD diagnosisTissue specimensAssessed patientsImmunohistochemistryMasson's trichromeValidation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials
Pulaski H, Mehta S, Manigat L, Kaufman S, Hou H, Nalbantoglu I, Zhang X, Curl E, Taliano R, Kim T, Torbenson M, Glickman J, Resnick M, Patel N, Taylor C, Bedossa P, Montalto M, Beck A, Wack K. Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials. The Journal Of Pathology Clinical Research 2024, 10: e12395. PMID: 39294925, PMCID: PMC11410674, DOI: 10.1002/2056-4538.12395.Peer-Reviewed Original ResearchConceptsClinical trialsAssessment of disease activityOverall percent agreementLiver biopsyDisease activityPathological assessmentWashout periodHistological assessmentEndpoint assessmentGold standardPercent agreementScoring systemExpert pathologistsSteatohepatitisAverage agreementDigital scoresPathologistsTrials
2023
Clinical and Pathological Correlation in Concomitant Celiac Disease and Eosinophilic Esophagitis Suggests Separate Etiologies
Castrodad-Rodríguez C, Cheng J, Westerhoff M, Liang G, Lin J, Nalbantoglu I, Hu S, Sekhri R, Panarelli N. Clinical and Pathological Correlation in Concomitant Celiac Disease and Eosinophilic Esophagitis Suggests Separate Etiologies. International Journal Of Surgical Pathology 2023, 32: 27-34. PMID: 37050846, DOI: 10.1177/10668969231167526.Peer-Reviewed Original ResearchConcomitant celiac diseaseEosinophilic esophagitisStudy patientsCeliac diseasePeak esophageal eosinophil countsCeliac disease symptomsMost study patientsGluten-free dietPatients meeting criteriaDisease-related symptomsEsophageal eosinophil countsDuodenal histologyAtopic conditionsEsophageal symptomsHistological severitySubepithelial fibrosisEosinophil countMarsh IIPathological featuresPathological correlationEsophagitisSeparate etiologiesPatientsMeeting criteriaControl groupApproach to the liver biopsy diagnosis of adult cholangiopathies
Nalbantoglu I, Misdraji J. Approach to the liver biopsy diagnosis of adult cholangiopathies. Diagnostic Histopathology 2023, 29: 23-35. DOI: 10.1016/j.mpdhp.2022.10.004.Commentaries, Editorials and LettersPrimary biliary cholangitisChronic biliary disordersBiliary cholangitisBiliary disordersPrimary sclerosing cholangitisLiver biopsy diagnosisAutoimmune hepatitisSclerosing cholangitisAdult patientsInflammatory variantClinical featuresHistologic featuresHistologic findingsBiopsy diagnosisDifferential diagnosisCholangitisCorrect diagnosisCholangiopathyClinical informationCareful assessmentDiagnosisDisordersWide spectrumVast majorityHepatitis
2022
Liver allograft findings of donation after cardiac death versus brain death in recipients with hepatitis C related cirrhosis: a matched histologic comparison
Byrnes K, Vachharajani N, Doyle MM, Nalbantoglu I. Liver allograft findings of donation after cardiac death versus brain death in recipients with hepatitis C related cirrhosis: a matched histologic comparison. Human Pathology 2022, 122: 25-31. PMID: 35085598, DOI: 10.1016/j.humpath.2022.01.005.Peer-Reviewed Original ResearchConceptsBiliary complicationsDCD casesLiver allograftsCardiac deathHistologic featuresBrain death (DBD) recipientsDCD liver allograftsPostoperative biliary complicationsBile duct injuryCold ischemia timeHepatitis C virusOrgan transplantation increasesBiliary alterationsDBD recipientsDCD allograftsDCD recipientsPortal edemaDuct injuryGraft survivalHepatitis CPortal inflammationOverall survivalTransplantation increasesLiver biopsyClinical outcomes
2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan
Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/s1470-2045(20)30683-5.Peer-Reviewed Original ResearchGastric Xanthoma
Abu‐Alreesh S, Rosen D, Nalbantoglu I, Arbizu RA. Gastric Xanthoma. Journal Of Pediatric Gastroenterology And Nutrition 2021, 73: e26-e26. PMID: 33605661, DOI: 10.1097/mpg.0000000000003085.Peer-Reviewed Case Reports and Technical NotesApobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis and hepatocellular cancer
Blanc V, Riordan JD, Soleymanjahi S, Nadeau J, Nalbantoglu I, Xie Y, Molitor EA, Madison BB, Brunt EM, Mills JC, Rubin DC, Ng I, Ha Y, Roberts LR, Davidson NO. Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis and hepatocellular cancer. Journal Of Clinical Investigation 2021, 131 PMID: 33445170, PMCID: PMC7773377, DOI: 10.1172/jci138699.Peer-Reviewed Original ResearchConceptsHuman hepatocellular cancerHigh-fructose dietHepatocellular cancerNonalcoholic fatty liver diseaseFatty liver diseaseExpression of mRNALipogenic gene expressionSpontaneous fibrosisAdvanced fibrosisLiver diseaseLiver functionHepatic steatosisInflammatory pathwaysInflammatory responseFed chowLong-term effectsTissue microarrayHepatic proliferationMRNA expressionFactor overexpressionReduced survivalFibrosisOxidative stressExtracellular matrix organizationSteatosis
2020
Recurrent Autoimmune Hepatitis and De Novo Autoimmune Hepatitis in the Liver Allograft
González IA, Hartley CP, Nalbantoglu I. Recurrent Autoimmune Hepatitis and De Novo Autoimmune Hepatitis in the Liver Allograft. American Journal Of Clinical Pathology 2020, 155: 435-445. PMID: 33252121, DOI: 10.1093/ajcp/aqaa147.Peer-Reviewed Original ResearchConceptsDe novo AIHOrthotopic liver transplantDe novo autoimmune hepatitisAutoimmune hepatitisNovo autoimmune hepatitisRecurrent AIHRecurrent autoimmune hepatitisGraft survivalPresentation of AIHModerate portal inflammationOverall graft survivalAggressive clinical courseSubmassive necrosisLiver allograftsLiver transplantPortal inflammationSevere hepatitisAggressive treatmentAdvanced fibrosisClinical courseClinicopathologic characteristicsFemale predominanceSevere inflammationHepatitisPatientsPrimary sclerosing cholangitis associated colitis: Characterization of clinical, histologic features, and their associations with liver transplantation
Aranake-Chrisinger J, Dassopoulos T, Yan Y, Nalbantoglu I. Primary sclerosing cholangitis associated colitis: Characterization of clinical, histologic features, and their associations with liver transplantation. World Journal Of Gastroenterology 2020, 26: 4126-4139. PMID: 32821074, PMCID: PMC7403798, DOI: 10.3748/wjg.v26.i28.4126.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseOrthotopic liver transplantationPSC-IBD patientsUlcerative colitisCrohn's diseasePSC-UCLiver transplantationHistologic featuresLeft colonPSC-UC patientsPrimary sclerosing cholangitisRight-sided diseaseWarrants clinical attentionDifferent disease phenotypesIBD durationIBD patientsPSC patientsSclerosing cholangitisUC patientsActive inflammationRectal involvementBowel diseaseClinical featuresPSC diagnosisLess steroids
2019
Cryptogenic cirrhosis: Old and new perspectives in the era of molecular and genomic medicine
Nalbantoglu I, Jain D. Cryptogenic cirrhosis: Old and new perspectives in the era of molecular and genomic medicine. Seminars In Diagnostic Pathology 2019, 36: 389-394. PMID: 31395291, DOI: 10.1053/j.semdp.2019.07.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCryptogenic cirrhosisCC casesLiver diseaseUnknown etiologyMain histologic findingsPossible genetic counselingChronic liver diseaseWhole-exome sequencingCirrhosis casesPediatric patientsTransplant eligibilityHistologic findingsHistologic patternPotential etiologiesHistologic examinationHistologic characterizationGenetic testingEtiologyPatientsExome sequencingDiagnostic abilityGenetic counselingGenetic alterationsDiagnosisNew disorder
2018
Clinical, Histologic, and Immunophenotypic Features of Serrated Polyps in Patients With Inflammatory Bowel Disease
Yang C, Tarabishy Y, Dassopoulos T, Nalbantoglu I. Clinical, Histologic, and Immunophenotypic Features of Serrated Polyps in Patients With Inflammatory Bowel Disease. Gastroenterology Research 2018, 11: 355-360. PMID: 30344807, PMCID: PMC6188039, DOI: 10.14740/gr1064w.Peer-Reviewed Original ResearchInflammatory bowel diseaseSSA/PsHyperplastic polypsSerrated polypsBowel diseaseSporadic serrated polypsLow-grade dysplasiaSessile serrated adenomas/polypsSerrated adenomas/polypsImmunohistochemistry staining patternsTraditional serrated adenomasSite-matched controlsColorectal serrated polypsAdenomas/polypsSporadic colorectal carcinomasOlder patientsClinicopathologic featuresImmunophenotypical featuresImmunophenotypic featuresColorectal carcinomaStudy groupPatientsSerrated adenomasStaining patternPolypsFrequent GNAQ and GNA14 Mutations in Hepatic Small Vessel Neoplasm
Joseph NM, Brunt EM, Marginean C, Nalbantoglu I, Snover DC, Thung SN, Yeh MM, Umetsu SE, Ferrell LD, Gill RM. Frequent GNAQ and GNA14 Mutations in Hepatic Small Vessel Neoplasm. The American Journal Of Surgical Pathology 2018, 42: 1201-1207. PMID: 29975248, DOI: 10.1097/pas.0000000000001110.Peer-Reviewed Original ResearchConceptsHepatic small vessel neoplasmVariant lesionsGNA14 mutationsVascular neoplasmLow-grade vascular neoplasmLow-grade neoplasmsVascular lesionsCavernous hemangiomaInfiltrative natureCytologic atypiaMolecular pathogenesisNeoplasmsPanel sequencingCopy number alterationsHotspot mutationsExome sequencingLesionsPathogenic mutationsSmall vesselsGNAQSame missense mutationNumber alterationsLiverMissense mutationsMutationsThe impact of diet‐induced hepatic steatosis in a murine model of hepatic ischemia/reperfusion injury
Liss KHH, McCommis KS, Chambers KT, Pietka TA, Schweitzer GG, Park SL, Nalbantoglu I, Weinheimer CJ, Hall AM, Finck BN. The impact of diet‐induced hepatic steatosis in a murine model of hepatic ischemia/reperfusion injury. Liver Transplantation 2018, 24: 908-921. PMID: 29729104, PMCID: PMC6097916, DOI: 10.1002/lt.25189.Peer-Reviewed Original ResearchConceptsDiet-induced hepatic steatosisSteatotic liversHepatic steatosisReperfusion injuryLiver diseaseMicrovesicular steatosisMurine modelObesity-associated nonalcoholic fatty liver diseaseHepatic ischemia/reperfusion injuryEnd-stage liver diseaseIschemia/reperfusion injuryNonalcoholic fatty liver diseasePlasma alanine aminotransferase levelsAlanine aminotransferase levelsFatty liver diseaseCriteria donor organsInflammatory cytokine concentrationsPotential therapeutic approachHepatic IRISteatotic graftsLiver transplantationAminotransferase levelsCommon indicationNonalcoholic steatohepatitisOrgan failureUnique causes of esophageal inflammation: a histopathologic perspective
Gopal P, Gibson JA, Lisovsky M, Nalbantoglu I. Unique causes of esophageal inflammation: a histopathologic perspective. Annals Of The New York Academy Of Sciences 2018, 1434: 219-226. PMID: 29766506, DOI: 10.1111/nyas.13732.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEsophageal mucosal biopsiesEsophageal inflammationMucosal biopsiesMedication-induced esophageal injuryCause of esophagitisSymptoms of esophagitisHerpes simplex virusBacterial esophagitisInfectious esophagitisSloughing esophagitisEsophageal manifestationsReflux esophagitisEosinophilic esophagitisEsophageal injuryHistopathologic featuresPathologic diagnosisHistopathologic perspectiveCommon causeDermatologic diseasesEsophagitisSimplex virusUnique causeBiopsyInflammationCauseThe microscopic anatomy of the esophagus including the individual layers, specialized tissues, and unique components and their responses to injury
Zhang X, Patil D, Odze RD, Zhao L, Lisovsky M, Guindi M, Riddell R, Bellizzi A, Yantiss RK, Nalbantoglu I, Appelman HD. The microscopic anatomy of the esophagus including the individual layers, specialized tissues, and unique components and their responses to injury. Annals Of The New York Academy Of Sciences 2018, 1434: 304-318. PMID: 29761508, DOI: 10.1111/nyas.13705.Peer-Reviewed Educational MaterialsConceptsSubmucosal nerve plexusNormal microscopic anatomyMicroscopic anatomyInlet patchSquamous liningSphincter mechanismNerve plexusSubmucosal glandsGastric mucosaGastrointestinal tractDistal aspectEsophageal wallIngested substancesEsophagusInjuryProximal partLymphatic vesselsPattern of reactionProtective functionStomachSpecific protective functionAnatomySpecific responsesSpecialized tissuesNerve
2017
Genomic regions associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture study
Sun X, Chandar AK, Canto MI, Thota PN, Brock M, Shaheen NJ, Beer DG, Wang JS, Falk GW, Iyer PG, Abrams JA, Venkat-Ramani M, Veigl M, Miron A, Willis J, Patil DT, Nalbantoglu I, Guda K, Markowitz SD, Zhu X, Elston R, Chak A. Genomic regions associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture study. PLOS ONE 2017, 12: e0184962. PMID: 29073141, PMCID: PMC5657624, DOI: 10.1371/journal.pone.0184962.Peer-Reviewed Original ResearchDifferentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014.
Fraum TJ, Tsai R, Rohe E, Ludwig DR, Salter A, Nalbantoglu I, Heiken JP, Fowler KJ. Differentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014. Radiology 2017, 286: 158-172. PMID: 28853673, DOI: 10.1148/radiol.2017170114.Peer-Reviewed Original ResearchConceptsNon-HCC malignanciesArterial phase hyperenhancementRim arterial phase hyperenhancementPositive predictive valueHepatocellular carcinomaPredictive valueData System (LI-RADS) version 2014Diagnostic performancePopulation of patientsHIPAA-compliant institutional review boardLiver Imaging ReportingLR-5 criteriaMalignant liver massesLI-RADS categoryFisher's exact testInstitutional review boardClinical followExtrahepatic malignanciesPathology findingsCommon findingLiver massExact testIndependent sample t-testMalignancyImaging ReportingHow does it feel to be a pathology resident? Results of a survey on experiences and job satisfaction during pathology residency
Pehlivanoglu B, Hassoy H, Calle C, Dendooven A, Nalbantoglu I, Reshchikova L, Gul G, Doganavsargil B. How does it feel to be a pathology resident? Results of a survey on experiences and job satisfaction during pathology residency. Virchows Archiv 2017, 471: 413-422. PMID: 28624995, DOI: 10.1007/s00428-017-2167-2.Peer-Reviewed Original ResearchConceptsHealth care systemPatient managementClinicians/surgeonsPathology residencyCountry's health care systemCommon reasonGross examinationMedical teamExperienced pathologistsTraining programResidency training programsPathologyCare systemMolecular pathologyPathologistsResidency program directorsPhysical working conditionsWeb-based linkMost respondentsPathology traineesTargeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis
McCommis KS, Hodges WT, Brunt EM, Nalbantoglu I, McDonald WG, Holley C, Fujiwara H, Schaffer JE, Colca JR, Finck BN. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology 2017, 65: 1543-1556. PMID: 28027586, PMCID: PMC5397348, DOI: 10.1002/hep.29025.Peer-Reviewed Original ResearchConceptsStellate cell activationPeroxisome proliferator-activated receptor γProliferator-activated receptor γNonalcoholic steatohepatitisMitochondrial pyruvate carrier 2Cell activationRodent modelsReceptor γDevelopment of NASHNonalcoholic fatty liver diseaseDose-limiting side effectHepatic stellate cell activationFatty liver diseaseInsulin-sensitizing thiazolidinedionesLiver of miceLiver-specific deletionExpression of markersTrans fatty acidsMetabolic syndromeLiver diseaseHepatocyte dysfunctionHepatic fibrosisLiver fibrosisPharmacologic developmentMouse model